Equities analysts expect DURECT Co. (NASDAQ:DRRX) to announce $4.60 million in sales for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for DURECT’s earnings. The lowest sales estimate is $3.00 million and the highest is $7.40 million. DURECT reported sales of $3.52 million in the same quarter last year, which indicates a positive year-over-year growth rate of 30.7%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, March 13th.

According to Zacks, analysts expect that DURECT will report full year sales of $4.60 million for the current fiscal year, with estimates ranging from $32.63 million to $37.03 million. For the next year, analysts forecast that the company will report sales of $22.67 million per share, with estimates ranging from $14.00 million to $37.00 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of analysts that that provide coverage for DURECT.

DURECT (NASDAQ:DRRX) last announced its earnings results on Wednesday, November 1st. The specialty pharmaceutical company reported $0.04 EPS for the quarter, beating analysts’ consensus estimates of ($0.05) by $0.09. DURECT had a negative net margin of 62.57% and a negative return on equity of 419.65%. The business had revenue of $20.75 million during the quarter, compared to analysts’ expectations of $5.09 million.

A number of equities research analysts have recently commented on DRRX shares. Laidlaw reduced their target price on shares of DURECT from $3.00 to $2.00 and set a “buy” rating for the company in a report on Friday, October 20th. HC Wainwright reissued a “hold” rating on shares of DURECT in a report on Thursday, November 2nd. Stifel Nicolaus cut shares of DURECT from a “buy” rating to a “hold” rating in a report on Friday, October 20th. Finally, ValuEngine raised shares of DURECT from a “sell” rating to a “hold” rating in a report on Tuesday, September 26th.

Institutional investors and hedge funds have recently modified their holdings of the business. Voya Investment Management LLC grew its position in DURECT by 22.8% during the second quarter. Voya Investment Management LLC now owns 82,826 shares of the specialty pharmaceutical company’s stock worth $129,000 after buying an additional 15,394 shares during the period. State of Wisconsin Investment Board acquired a new position in DURECT during the second quarter worth about $151,000. The Manufacturers Life Insurance Company grew its position in DURECT by 12.1% during the second quarter. The Manufacturers Life Insurance Company now owns 120,977 shares of the specialty pharmaceutical company’s stock worth $189,000 after buying an additional 13,072 shares during the period. Rhumbline Advisers grew its position in DURECT by 12.0% during the second quarter. Rhumbline Advisers now owns 175,604 shares of the specialty pharmaceutical company’s stock worth $274,000 after buying an additional 18,871 shares during the period. Finally, Schwab Charles Investment Management Inc. grew its position in DURECT by 61.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 263,476 shares of the specialty pharmaceutical company’s stock worth $467,000 after buying an additional 100,200 shares during the period. Institutional investors own 44.69% of the company’s stock.

Shares of DURECT (NASDAQ:DRRX) traded down $0.02 during trading hours on Friday, hitting $0.92. 608,604 shares of the stock were exchanged, compared to its average volume of 704,768. DURECT has a 1-year low of $0.74 and a 1-year high of $2.17. The company has a quick ratio of 1.57, a current ratio of 1.67 and a debt-to-equity ratio of 1.46. The stock has a market capitalization of $138.15, a PE ratio of -6.13 and a beta of 1.69.

COPYRIGHT VIOLATION NOTICE: This report was published by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The correct version of this report can be accessed at https://www.watchlistnews.com/durect-co-drrx-expected-to-post-quarterly-sales-of-4-60-million/1787913.html.

About DURECT

Durect Corporation is a biopharmaceutical company with research and development programs. The Company’s products candidates include DUR-928, oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other product candidates include POSIMIR (controlled release injection of bupivacaine), REMOXY (oral controlled release oxycodone), ORADUR-ADHD, ELADUR (controlled release injection of bupivicane), Relday (risperidone), ORADUR-based opioid (hydromorphone) and SABER-based ophthalmic.

Get a free copy of the Zacks research report on DURECT (DRRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for DURECT (NASDAQ:DRRX)

Receive News & Ratings for DURECT Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DURECT and related companies with MarketBeat.com's FREE daily email newsletter.